An additional observed resistance mechanism of AML cells to FLT3 inhibitors also includes the activation of alternative tyrosine kinase signaling pathways, such as the activation of the tyrosine kinase receptor AXL and other only partly investigated pathways in AML [18,19,20]. This evidence concerns the gene FLT3 and acute myeloid leukemia.